InflaRx jumps on FDA's emergency-use authorization for COVID injection

Inflarx NV

05/04/2023 15:27

(Updates)
    ** U.S.-listed shares  IFRX.O  of Germany-based biopharma
company InflaRx rise 55.7% to ~$5, hit more than 2-year high
    ** U.S. FDA grants emergency-use authorization to company's
monoclonal antibody, Vilobelimab, to treat critically ill
COVID-19 patients when administered within 48 hours of receiving
artificial life support
    ** Vilobelimab, also known as Gohibic, controls a protein
that plays an important and often harmful role in the body's
immune response
    ** IFRX continues talks with FDA to discuss next step toward
submitting application for full approval
    ** Including session's gains, company's U.S.-listed shares
up 80.6% YTD

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com))